Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,230.12
(
0.29%
)
US TECH 100
26,942.00
(
0.87%
)
Dow Jones
49,499.27
(
-0.31%
)
Brent Oil
107.80
(
0.00%
)
Bitcoin
78,469.24
(
-0.27%
)
News Focus
News Focus
Post# of 347009
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

biopharm

Send PM Follow Ignore
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

biopharm

Re: cjgaddy post# 269146

Thursday, 07/28/2016 2:49:03 PM

Thursday, July 28, 2016 2:49:03 PM

Post# of 347009
Thanks CJ and Looks to align with these puzzle pieces... July 2015 publication exosomes and I am sure Kelly is aware of PS Targeting re: new borns

https://au.linkedin.com/in/kelly-mckelvey-61117521

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote